Ricevi le ultime notizie sulle azioni AnaptysBio con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ANAB

Ultime notizie per

ANAPTYSBIO INC

AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Inc

News

Press Releases

Anaptys Announces Participation in March Investor Conferences

Markets

Anaptys Announces Stock Repurchase Plan

Management

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Earnings

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Participation in September Investor Conferences

Small Cap

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

ANAB

DSGN

HLXA

PSTX

XERS

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Bicara Therapeutics

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Geron

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kura Oncology

MiMedx Group

Oruka Therapeutics

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Relay Therapeutics

Rezolute

ARS Pharmaceuticals

Spyre Therapeutics

Upstream Bio

UroGen Pharma

Valneva

Vir Biotechnology

Xencor

Wedbush

HC Wainwright & Co.

JP Morgan

Guggenheim

Comments

AnaptysBio Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO